Protein tyrosine kinase inhibitors as anticancer agents

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 1, 2004, Pages 35-53

  Supuran, Claudiu T ^a   Scozzafava, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Drug design; Epidermal growth factor (EGF); Imatinib; Inhibitor; Tyrosine kinase; Vascular endothelial growth factor (VEGF)

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMIDE; ANTINEOPLASTIC AGENT; CANERTINIB; EKB 0569; ENZYME ANTIBODY; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; IMATINIB; ISOQUINOLINE DERIVATIVE; LAPATINIB; MESYLIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE DERIVATIVE; OROSOMUCOID INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VETALANIB;

APOPTOSIS; CANCER CHEMOTHERAPY; CATALYSIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG INDUSTRY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE ACTIVATION; GENETIC CODE; HUMAN; HUMAN GENOME; NONHUMAN; ONCOGENE; PATENT; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0347286815     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.1.35     Document Type: Review

References (24)

1. SUN L, MCMAHON G: Inhibition of rumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Dev. Today (2000) 5:344-353.
2. FABBRO D, PARKINSON D, MATTER A: Protein tyrosine kinase inhibitors: new treatment modalities ? Curr. Opin. Pharmacol. (2002) 2:374-381.
3. LEVITZKI A: Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer. (2002) 38(Suppl.5):S11-S18.
4. LEE AV, SCHIFF R, CUI X et al.: New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin. Cancer Res. (2003) 9:516S-523S.
5. RITTER CA, ARTEAGA CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. (2003) 30(Suppl.1):3-11.
6. CROOM KF, PERRY CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs (2003) 63:513-522.
7. DREVS J, MEDINGER M, SCHMIDT-GERSBACH C, WEBER R, UNGER C: Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets (2003) 4:113-121.
8. MANLEY PW, COWAN-JACOB SW, BUCHDUNGER E et al.: Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer (2002) 38 (Suppl.5):S19-S27.
9. HUBBARD SR: Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. (2002) 12:735-741.
10. SATTLER M, PRIDE YB, MA P et al.: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. (2003) 63:5462-5469.
11. GEORGE D: Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. (2003) 532:141-151.
12. SATTLER M, SCHEIJEN B, WEISBERG E, GRIFFIN JD: Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv. Exp. Med. Biol. (2003) 532:121-140.
13. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
14. TALPAZ M, SILVER RT, DRUKER BJ et al.: Gleevec induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928-1937.
15. THIESING JT, OHNO-JONES S, KOLIBABA KS, DRUKER BJ: Efficacy of STI-571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood (2000) 96:3195-3199.
16. BONOMI P: Clinical studies with non-Iressa EGFR tyrosine kinase inhibitors. Lung Cancer (2003) 41 (Suppl.1):S43-S48.
17. SCHUENEMAN AJ, HIMMELFARB E, GENG L et al.: SU-11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. (2003) 63:4009-4016.
18. WAKELING AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. (2002) 2:382-387.
19. BONOMI P: Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin. Investig. Drugs. (2003) 12:1395-1401.
20. WANG Y, METCALF CA, SHAKESPEARE WC et al.: Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. (2003) 13:3067-3070.
21. RACHID Z, BRAHIMI F, KATSOULAS A, TEOH N, JEAN-CLAUDE BJ: The combi-targeting concept: chemical dissection of the dual targeting properties of a series of 'combitriazenes'. J. Med. Chem. (2003) 46:4313-4321.
22. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD-1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer. Res. (2001) 7:1459-1465.
23. RANSON M, HAMMOND LA, FERRY D et al.: ZD-1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. (2002) 20:2240-2250.
24. DREVS J, SCHMIDT-GERSBACH C, MROSS K et al.: Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK-787/ZK-222584 (PTK/ZK) in two clinical Phase I trials. Proc. ASCO (2002) 85a:Abstract 337.